Spanish biotech Sanifit is targeting calcification disorders, and says it could have a potential multi-billion dollar treatment in two kidney failure indications.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.